NCT04833764 is a Phase 1, PHASE2 clinical trial of Rosuvastatin in Post-thrombotic Syndrome, sponsored by Khanh Nguyen.

Who is sponsoring NCT04833764?

NCT04833764 is sponsored by Khanh Nguyen.

What drugs are being tested in NCT04833764?

Interventions in NCT04833764: Rosuvastatin.

What condition does NCT04833764 study?

NCT04833764 studies Post-thrombotic Syndrome, Deep Vein Thrombosis Leg.

Is NCT04833764 still recruiting?

NCT04833764 is currently status unknown. Last updated 15 October 2021.

Last reviewed 2021-10-15 · How we verify

NCT04833764

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mechanisms of Deep Vein Thrombosis (DVT) and Vein Wall Fibrosis

Status unknown Phase 1, PHASE2 Last updated 15 October 2021

What this trial tests

Phase 1, PHASE2 trial testing Rosuvastatin in Post-thrombotic Syndrome in 30 participants. Status unknown.

Timeline

1 June 2021

Primary endpoint
1 June 2025

1 June 2025

Quick facts

Lead sponsor	Khanh Nguyen
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	30
Start date	1 June 2021
Primary completion	1 June 2025
Estimated completion	1 June 2025
Sites	1 location across United States

Drugs / interventions tested

Rosuvastatin (rosuvastatin) — full drug profile →

Conditions studied

Post-thrombotic Syndrome — all drugs for Post-thrombotic Syndrome →
Deep Vein Thrombosis Leg — all drugs for Deep Vein Thrombosis Leg →

Sponsor

Khanh Nguyen

Who can join

Adults 18 to 85, any sex, with Post-thrombotic Syndrome or Deep Vein Thrombosis Leg. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to determine the safety and tolerability or efficacy of adjunctive treatments (including rosuvastatin 20 mg daily) in combination with standard anticoagulation therapy (Factor Xa inhibitors) in patients with lower extremity deep vein thrombosis (DVT). The efficacy of adjunctive treatments to prevent the development of post thrombotic syndrome (PTS) after DVT will be evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Rosuvastatin

Trials testing the same drug.

NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
NCT07534592 — A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants · Phase 1 · not yet recruiting
NCT07515339 — A Study to Learn More About How Safe Nurandociguat is and How it Affects the Way the Body Processes Rosuvastatin and Dab · Phase 1 · not yet recruiting
NCT07303816 — Statins to Prevent Cancer Associated Blood Clots · Phase 4 · not yet recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04833764 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Khanh Nguyen
Last refreshed: 15 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04833764.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing